Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Apr 12, 2013 3:28pm

309 Views

Post# 21248467

RE: RE: RE: stock broker

I think there were 4 maybe 5 callers in the Q/A period. Nothing too novel. I only remember two noteworthies:

1) Someone asked about RVX:TSX vs. RVXCF (US market). This subject has been exhaustively discussed on this board since.

2) Someone asked about whether Resverlogix will make an end of dosing announcement for ASSURE in the next two weeks, and Don replied that similar to the end of dosing in past trials, yes they will make an announcment (though he did not explicitly indicate that it would be w/i two weeks).

Anyone else remember more?

Bullboard Posts

Investor’s corner: Solving chronic pain in dogs – A significant market opportunity